Published in Cancer on January 03, 2012
Primary dural repair in minimally invasive spine surgery. Case Rep Med (2013) 0.79
Incidence of primary spinal cord, spinal meninges, and cauda equina tumors in Korea, 2006-2010. Cancer Res Treat (2014) 0.78
Resection of filum terminale ependymoma. Eur Spine J (2013) 0.77
Histologic grade and extent of resection are associated with survival in pediatric spinal cord ependymomas. Childs Nerv Syst (2013) 0.77
A Nation-Wide Epidemiological Study of Newly Diagnosed Primary Spine Tumor in the Adult Korean Population, 2009-2011. J Korean Neurosurg Soc (2017) 0.75
(18)F-fluoroethyl-L-tyrosine positron emission tomography-guided diagnosis of a malignant intramedullary spinal cord tumor. Oncol Lett (2016) 0.75
Intramedullary Spinal Cord Tumors: Part I-Epidemiology, Pathophysiology, and Diagnosis. Global Spine J (2015) 0.75
Incidence, histopathology, and surgical outcome of tumors of spinal cord, nerve roots, meninges, and vertebral column - Data based on single institutional (Sher-i-Kashmir Institute of Medical Sciences) experience. J Neurosci Rural Pract (2016) 0.75
Intraoperative ultrasound in spinal tumor surgery. J Ultrasound (2014) 0.75
Intraoperative Neurophysiological Monitoring for Spinal Cord Tumor Surgery: Comparison of Motor and Somatosensory Evoked Potentials According to Tumor Types. Ann Rehabil Med (2017) 0.75
Impact of spinal cord compression from intradural and epidural spinal tumors on perioperative symptoms-implications for surgical decision making. Neurosurg Rev (2016) 0.75
Epidemiology of central nervous system tumors in Labin area, Croatia, 1974-2001. Croat Med J (2004) 1.68
Trends in incidence of brain and central nervous system tumors in Norway, 1970-1999. Neuroepidemiology (2004) 1.62
Prevalence estimates for primary brain tumors in the United States by behavior and major histology groups. Neuro Oncol (2001) 1.57
Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges, or cauda equina. J Neurosurg Spine (2010) 1.54
Descriptive epidemiology of primary spinal cord tumors. J Neurooncol (2007) 1.52
Epidemiology of primary central nervous system tumors in Estonia. Neuroepidemiology (2000) 1.16
Incidence of central nervous system tumors in Gironde, France. Neuroepidemiology (2004) 1.09
Central nervous system tumors among Koreans--a statistical study on 697 cases. J Korean Med Sci (1989) 1.02
Descriptive epidemiology of primary tumors of the spinal cord and spinal meninges in Los Angeles County, 1972-1985. Neuroepidemiology (1990) 0.96
The frequency of intracranial and intraspinal neoplasms in the resident population of Rochester, Minnesota. J Neurosurg (1958) 0.91
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature (2006) 27.91
Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med (2007) 16.95
CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol (2012) 8.16
Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst (2008) 8.14
TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A (2013) 6.88
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res (2006) 6.77
Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol (2010) 6.30
CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. Neuro Oncol (2013) 6.19
Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell (2009) 5.81
Annual report to the nation on the status of cancer, 1975-2007, featuring tumors of the brain and other nervous system. J Natl Cancer Inst (2011) 5.09
Concentrations of serum vitamin D and the metabolic syndrome among U.S. adults. Diabetes Care (2005) 4.47
Consensus Conference on Brain Tumor Definition for registration. November 10, 2000. Neuro Oncol (2002) 4.30
Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res (2004) 4.26
Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature (2012) 4.13
Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer (2008) 3.98
Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol (2003) 3.83
Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell (2010) 3.82
Sedentary behavior, physical activity, and the metabolic syndrome among U.S. adults. Obes Res (2005) 3.68
The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle (2009) 3.55
Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell (2013) 3.32
Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell (2009) 3.11
Sensitive detection of human cytomegalovirus in tumors and peripheral blood of patients diagnosed with glioblastoma. Neuro Oncol (2007) 2.99
Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res (2008) 2.97
The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet (2013) 2.89
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Migraine and coronary heart disease in women and men. Headache (2002) 2.44
c-Myc is required for maintenance of glioma cancer stem cells. PLoS One (2008) 2.41
Brief communication: The prevalence of high intake of vitamin E from the use of supplements among U.S. adults. Ann Intern Med (2005) 2.39
Identification of OTX2 as a medulloblastoma oncogene whose product can be targeted by all-trans retinoic acid. Cancer Res (2005) 2.35
Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J Clin Oncol (2008) 2.32
Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol (2003) 2.16
An animal model of MYC-driven medulloblastoma. Cancer Cell (2012) 2.12
Brain cancer stem cells display preferential sensitivity to Akt inhibition. Stem Cells (2008) 2.12
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell (2011) 2.04
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastoma. Neuro Oncol (2010) 1.99
Targeting interleukin 6 signaling suppresses glioma stem cell survival and tumor growth. Stem Cells (2009) 1.97
Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes. Oncotarget (2010) 1.88
Temporal trends in incidence of primary brain tumors in the United States, 1985-1999. Neuro Oncol (2006) 1.86
Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin Cancer Res (2003) 1.85
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme. J Clin Oncol (2005) 1.85
Prevalence estimates for primary brain tumors in the United States by age, gender, behavior, and histology. Neuro Oncol (2010) 1.83
OTX2 is critical for the maintenance and progression of Shh-independent medulloblastomas. Cancer Res (2009) 1.77
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell (2011) 1.77
The metabolic syndrome and concentrations of C-reactive protein among U.S. youth. Diabetes Care (2005) 1.72
Health-related quality of life and health risk behaviors among smokers. Am J Prev Med (2005) 1.72
Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther (2005) 1.66
Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol (2009) 1.65
Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. J Clin Oncol (2005) 1.63
Phase 1 trial of gefitinib plus sirolimus in adults with recurrent malignant glioma. Clin Cancer Res (2006) 1.63
Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. Arch Pathol Lab Med (2008) 1.61
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumors. Neuro Oncol (2008) 1.59
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol (2010) 1.59
Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med (2007) 1.57
Cognitive functioning as a predictor of functional disability in later life. Am J Geriatr Psychiatry (2006) 1.55
Monoclonal antibody blockade of IL-2 receptor α during lymphopenia selectively depletes regulatory T cells in mice and humans. Blood (2011) 1.54
Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma. J Clin Oncol (2009) 1.53
Descriptive epidemiology of primary spinal cord tumors. J Neurooncol (2007) 1.52
Descriptive epidemiology of vestibular schwannomas. Neuro Oncol (2006) 1.51
Phase II trial of carmustine plus O(6)-benzylguanine for patients with nitrosourea-resistant recurrent or progressive malignant glioma. J Clin Oncol (2002) 1.50
Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res (2012) 1.46
Defining future directions in spinal cord tumor research: proceedings from the National Institutes of Health workshop. J Neurosurg Spine (2010) 1.45
Melanoma survival in the United States, 1992 to 2005. J Am Acad Dermatol (2011) 1.44
Improved survival time trends for glioblastoma using the SEER 17 population-based registries. J Neurooncol (2011) 1.42
Splenda alters gut microflora and increases intestinal p-glycoprotein and cytochrome p-450 in male rats. J Toxicol Environ Health A (2008) 1.41
Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas. Oncotarget (2014) 1.40
EGFRvIII-targeted vaccination therapy of malignant glioma. Brain Pathol (2009) 1.40
MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. Arch Pathol Lab Med (2002) 1.37
The impact of the Benign Brain Tumor Cancer Registries Amendment Act (Public Law 107-260) on non-malignant brain and central nervous system tumor incidence trends. J Registry Manag (2013) 1.35
TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathol (2013) 1.35
Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J Clin Oncol (2002) 1.32
Direct in vivo evidence for tumor propagation by glioblastoma cancer stem cells. PLoS One (2011) 1.29
Phase II study of carboplatin, irinotecan, and bevacizumab for bevacizumab naïve, recurrent glioblastoma. J Neurooncol (2011) 1.29
Distribution of serum concentrations of alpha-tocopherol and gamma-tocopherol in the US population. Am J Clin Nutr (2006) 1.28
Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol (2010) 1.27
Brain tumors in mice are susceptible to blockade of epidermal growth factor receptor (EGFR) with the oral, specific, EGFR-tyrosine kinase inhibitor ZD1839 (iressa). Clin Cancer Res (2002) 1.27
Issues of diagnostic review in brain tumor studies: from the Brain Tumor Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev (2008) 1.25
Neighborhood change and distant metastasis at diagnosis of breast cancer. Ann Epidemiol (2007) 1.25
Protocol for the examination of specimens from patients with tumors of the brain/spinal cord. Arch Pathol Lab Med (2008) 1.25
Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. Neurosurgery (2002) 1.23
Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol (2012) 1.22
A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun (2009) 1.22
Association of cutaneous melanoma incidence with area-based socioeconomic indicators-United States, 2004-2006. J Am Acad Dermatol (2011) 1.20
Trends in endometrial cancer incidence rates in the United States, 1999-2006. J Womens Health (Larchmt) (2011) 1.17
A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. J Natl Compr Canc Netw (2011) 1.16
Malignant pineal germ-cell tumors: an analysis of cases from three tumor registries. Neuro Oncol (2008) 1.16
Phase 2 study of carboplatin, irinotecan, and bevacizumab for recurrent glioblastoma after progression on bevacizumab therapy. Cancer (2011) 1.16
ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. Clin Cancer Res (2005) 1.16
Global identification of MLL2-targeted loci reveals MLL2's role in diverse signaling pathways. Proc Natl Acad Sci U S A (2012) 1.14
Laminin alpha 2 enables glioblastoma stem cell growth. Ann Neurol (2012) 1.13
Trends in risk factors for cardiovascular disease among children and adolescents in the United States. Pediatrics (2004) 1.13